指南与共识肝病消化道肿瘤与早癌消化内镜

MASLD患者结直肠癌风险:国际德尔菲共识声明

Colorectal cancer in metabolic dysfunction-associated steatotic liver disease: an international Delphi consensus statement.
指南 / 共识 · Gut · 2026-09-07

该国际德尔菲共识由35名多学科专家对17条声明达成一致,认为MASLD与结直肠癌风险增加相关,代谢负担进一步增加风险,MASLD严重程度与结直肠癌患者更差结局相关,建议早期风险适配筛查和综合代谢管理。

要点

  • MASLD患者结直肠癌风险增加,代谢负担进一步增加风险。
  • MASLD严重程度与结直肠癌患者更差结局相关。
  • 建议对MASLD人群更早、风险适配筛查和综合代谢管理。

核心结论

  • 专家小组强调对MASLD个体需提高结直肠癌临床警惕性。
  • 共识支持转向更早、风险适配筛查和综合代谢管理以减轻MASLD人群结直肠癌负担。

研究设计与样本

  • 由来自亚洲、欧洲、北美、南美、大洋洲和非洲多医学领域的35名国际专家进行德尔菲调查。
  • 专家评估三个领域(流行病学、发病机制和管理)的17条声明。

主要发现

  • 所有17条声明均达成共识。
  • MASLD与结直肠癌风险增加相关,代谢负担进一步增加此风险。
  • MASLD严重程度与MASLD合并结直肠癌患者更差结局相关。
  • 肠-肝轴和肠道菌群失调在MASLD和结直肠癌发展中起关键作用,瘦素和脂联素也可能参与。

关键数值与推荐

  • 生活方式干预减重、早期结直肠癌筛查、减重手术和使用GLP-1受体激动剂被强调为潜在风险降低策略。

临床怎么用

  • 对MASLD个体应提高结直肠癌警惕性,考虑更早、风险适配的筛查。
  • 将综合代谢管理纳入MASLD患者结直肠癌风险降低策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide. Epidemiological evidence indicates that MASLD is associated with an increased risk of developing colorectal cancer (CRC). MASLD and CRC share many common risk factors and pathophysiological mechanisms, but an optimal strategy for identifying and managing CRC risk in individuals with MASLD remains lacking. OBJECTIVE: This study aimed to achieve consensus on the risk of CRC in individuals with MASLD. DESIGN: A Delphi survey was conducted by a multidisciplinary panel of 35 international experts from diverse medical fields across Asia, Europe, North America, South America, Oceania and Africa. Experts evaluated 17 statements across three domains: epidemiology, pathogenesis and management. RESULTS: Consensus was achieved on all 17 statements. MASLD is associated with an increased risk of CRC, and metabolic burden further increases this risk. Furthermore, the severity of MASLD is associated with worse outcomes in patients with MASLD and CRC. The gut-liver axis and gut dysbiosis play key roles in the development of MASLD and CRC, while leptin and adiponectin may also be involved. Weight loss with lifestyle interventions, early CRC screening, bariatric surgery and use of GLP-1 receptor agonists are highlighted as potential risk-reduction strategies. CONCLUSION: The expert panel emphasises the need for greater clinical vigilance for CRC among individuals with MASLD. This consensus supports a paradigm shift towards earlier, risk-adapted screening and integrated metabolic management to reduce the burden of CRC in the MASLD population.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Wu CT, Targher G, Byrne CD, et al. Colorectal cancer in metabolic dysfunction-associated steatotic liver disease: an international Delphi consensus statement. Gut. 2026. PMID: 41770836. doi:10.1136/gutjnl-2025-337374

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。